News & Events

Cambridge, MA – August 5, 2014 – Neurovance, Inc. today announced that Brigitte Robertson, MD, has been appointed Vice President of Clinical Development. Dr. Robertson brings Neurovance nearly 20 years of expertise as a board certified adult, child and adolescent psychiatrist specializing in attention deficit hyperactivity disorder (ADHD), with over 15 years of clinical development experience focused on ADHD treatments. Most recently, Dr. Robertson served as Global Development Strategy Team Lead, Senior Director at Shire Pharmaceuticals, where she led multiple cross-functional global development teams and was accountable for the development strategy and execution for several development programs in ADHD involving Intuniv, SPD465 and Vyvanse, the leading ADHD franchise worldwide. Dr. Robertson will contribute to the development of Neurovance’s centanafadine SR (formerly EB-1020 SR), a non-stimulant being developed for the treatment of adults with ADHD.

 “Brigitte brings to Neurovance a clinician’s knowledge of and experience working in ADHD, which greatly enhances our capability to deliver successful trials,” said Anthony A. McKinney, President and CEO of Neurovance. “Brigitte’s experience and leadership in the clinical development of ADHD therapeutics, including the stimulants Vyvanse and SPD465 and the non-stimulant Intuniv, will be invaluable in shaping the centanafadine development program and optimizing its value.”

 Neurovance expects to prove that centanafadine SR, a norepinephrine- and dopamine-preferring triple reuptake inhibitor, has the right ratio for the right patient. Data from a phase 2a trial of centanafadine SR demonstrated efficacy in a range similar to stimulants, the leading medications used to treat ADHD currently. A human abuse liability (HAL) study is currently underway to evaluate the abuse liability potential for centanafadine among qualified recreational stimulant users. Neurovance recently received notification that the United States Adopted Name (USAN) Council and World Health Organization accepted “centanafadine” as the non-proprietary name for EB-1020.

“I see tremendous potential for centanafadine SR as a novel hybrid approach to ADHD treatment that combines the best features of stimulants and non-stimulants to avoid some of the abuse liability issues associated with the stimulants while achieving a similar level of efficacy,” said Dr. Robertson. “I am excited to join the Neurovance team advancing the development of this new treatment option for patients."

 Dr. Robertson completed her residency in Adult Psychiatry at the University of Colorado Health Sciences Center and a subsequent Child Psychiatry fellowship and NIMH Psychopharmacology Research fellowship with an emphasis on neuroimaging at the University of California San Diego. She joins Neurovance with significant clinical and industry experience including senior roles at CCP Children’s Hospital in San Diego, and Glaxo and Sepracor, where she gained extensive experience across leadership roles in early discovery and late-stage development across a broad array of disorders and mechanisms in psychiatry and neurology (e.g. schizophrenia, bipolar, depression, anxiety, ADHD, insomnia, PTSD and Fragile X). Dr. Robertson received an MD from Georgia Health Sciences University. She has published

several peer-reviewed articles and is active in advocacy groups for the advancement of pediatric therapeutics.

About ADHD

Adult ADHD is a very serious medical condition. Approximately 10 million American adults are diagnosed with ADHD, but only one in ten receives diagnosis and treatment. Adult ADHD is often associated with serious psychiatric comorbidities, including depression, anxiety and substance abuse. According to the most recent data from IMS Health, the 2013 US ADHD prescription market for adults is now larger than that for children, with 30 million and 29 million total prescriptions written, respectively. Total US sales for ADHD in 2013 were approximately $10 billion, according to IMS.

About Neurovance

Neurovance is a clinical stage neuroscience-focused company developing centanafadine SR for adult attention deficit hyperactivity disorder (ADHD). Neurovance is led by co-founder Anthony McKinney and other seasoned drug developers who have been involved in the development of several successful neuroscience medications. Neurovance is a privately held company with headquarters in Cambridge, Massachusetts. Additional information can be found on the Neurovance website at www.neurovance.com.

Contacts:

Neurovance Anthony A. McKinney, 617-758-0300

Jennifer Anderson (New York), 646-237-6926

Stephen Gendel (Los Angeles), 310-878-4652

Media: Initiate PR

Jennifer Anderson (New York), 646-237-6926

Stephen Gendel (Los Angeles), 310-878-4652